- Hoechst Marion Roussel has filed for marketing clearance of itsantibiotic Tavanic (levofloxacin) with the UK Medicines Control Agency. Approval in the UK is expected by September of this year, and in the European Union by April 1998. The antibiotic, which is from the quinolone class and has been tested in a range of indications including sepsis, intra-abdominal infections and sinusitis, is particularly effective in the treatment of respiratory tract diseases, says the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze